Creating new drugs to help treat resistant breast and lung cancers
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
This study is looking at new ways to stop certain proteins that help cancer cells resist treatment, especially in HER2-positive breast cancer and KRAS-driven lung cancer, with the hope of creating better therapies that work more effectively for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10900479 on NIH RePORTER |
What this research studies
This research focuses on developing new inhibitors that target CDK12 and CDK13, which are proteins involved in cancer cell adaptation to treatments. By blocking these proteins, the goal is to prevent cancer cells from becoming resistant to therapies, particularly in HER2-positive breast cancers and KRAS-driven lung cancers. The research involves identifying how these proteins change cancer cell behavior and finding ways to exploit these changes to improve treatment outcomes. Patients may benefit from new therapies that are more effective against their cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with HER2-positive breast cancer or KRAS-driven lung cancer who have experienced treatment resistance.
Not a fit: Patients with cancers that do not involve HER2 or KRAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with resistant breast and lung cancers.
How similar studies have performed: Previous research has shown promise in targeting CDK12 and CDK13 to combat drug resistance in cancer, indicating a potential for success in this approach.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Duckett, Derek Ronald — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Duckett, Derek Ronald
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.